Baudax Bio, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
  • R&D
    • Product Portfolio
    • ANJESO® (meloxicam) injection
    • NMB & Reversal Agent
    • Investigator Sponsored Research
  • Therapeutic Areas
    • Post-Operative Pain
    • Anesthesia
  • News & Investors
    • Overview
    • Press Releases
    • Events
    • Presentations
    • Governance
    • Stock Info
    • Financial & Filings
  • Contact
  • Careers

Press Releases

News & Investors

News & Investors

  • Overview
  • Press Releases
  • Events
  • Presentations
  • Governance
    • Governance Documents
    • Board of Directors
    • Board Committees
  • Stock Info
    • Form 8937
  • Financial & Filings
    • Overview
    • All SEC Filings

Baudax Bio Reports 2021 Fourth Quarter and Annual Financial Results

Mar 16, 2022 8:00am EDT

Baudax Bio to Present at the Oppenheimer 32nd Annual Healthcare Conference

Mar 10, 2022 7:00am EST

Baudax Bio Initiates Phase IV Clinical Trial Evaluating ANJESO® in Pediatric Patients Following Surgery

Mar 08, 2022 8:00am EST

Baudax Bio Regains Compliance with NASDAQ Listing Requirements

Mar 07, 2022 8:00am EST

Baudax Bio Announces Seventh Orange Book Listable Patent for ANJESO®

Mar 02, 2022 7:00am EST

Baudax Bio Announces Pricing of $10.0 Million Public Offering

Feb 24, 2022 11:23pm EST

Baudax Bio Announces Proposed Public Offering of Securities

Feb 24, 2022 4:40pm EST

Baudax Bio Announces 1-for-35 Reverse Stock Split

Feb 15, 2022 8:29pm EST

Baudax Bio to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

Jan 04, 2022 7:00am EST

Baudax Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 31, 2021 4:05pm EST
RSS
  • Prev
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...11
    Next
    • Email Alerts
    • Tear Sheet
    • RSS News Feed
    © 2023 Baudax Bio, Inc. All Rights Reserved. ANJESO is a registered trademark of Baudax Bio, Inc.
    Privacy Policy Terms of Use Disclaimer Sitemap